Immunohistochemistry of a component protein of the breast cystic disease fluid with mol. wt 15,000

Doussal, V. Le; Zangerle, P. F.; Collette, Julien; Spyratos, Frédérique; Hacène, K.; Brière, M.; Franchimont, P; Gest, J

doi:10.1016/0277-5379(85)90269-x

Cited by 24 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous study (Bundred et al, 1987a) has shown that staining of tumour cells with an antiserum to zinc M2 glycoprotein is a reliable immunohistochemical marker of apocrine differentiation in tumours. Workers using an antibody to another cyst protein, GCDFP 15, have confirmed that tumour apocrine differentiation can be objectively diagnosed using immunohistochemistry and found an incidence of 50-80% of tumours exhibiting some degree of apocrine change (Mazoujian et al, 1983;Miller et al, 1988;Le Dousal et al, 1985). The incidence of 55% of tumours exhibiting staining in this study is in broad agreement with these figures.…”

Section: Prognostic Factorssupporting

confidence: 88%

“…Two previous studies of tumour apocrine change using antisera to GCDFP 15 have shown an association between better differentiated tumours and immunohistochemically determined GCDFP 15 expression (Le Dousal et al, 1985) and high cytosol GCDFP 15 levels (Silva et al, 1982). We were able to substantiate these findings, the better differentiated carcinomas being less likely to be negative in comparision to the poorly differentiated tumours although the association was a weak one.…”

Section: Prognostic Factorsmentioning

confidence: 95%

See 1 more Smart Citation

Is apocrine differentiation in breast carcinoma of prognostic significance?

Bundred

Walker²,

Everington³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary Apocrine differentiation in human breast cancers has been assessed using immunohistochemistry to detect zinc a2 glycoprotein and the findings related to standard prognostic factors, disease free interval (DFI) and survival in 145 women with early breast cancer. Breast tumour samples from women with a minimum follow-up of 5 years were assessed. Routinely fixed and processed tissue was used throughout. Sixty-six (45%) tumours did not stain with the antibody. Fifty-two (36%) exhibited positive apocrine staining while for 27 (19%) only a few cells were reactive. The presence of apocrine differentiation was unrelated to lymph node status, menstrual status, tumour grade or size, oestrogen receptor (E2R) or progesterone receptor status. However, patients whose tumours exhibited apocrine staining had a shorter disease-free interval (DFI) (P = 0.03) and survival (P = 0.03). A Cox's multiple regression analysis of the data found that the presence of staining added significantly (P = 0.047) to the predictive value of node status (P = 0.0001), menstrual status (P = 0.0001), tumour size (P = 0.0026) and E2R status (P = 0.0014) for patient survival. The other seven prognostic factors tested did not reach significance and were rejected from the model. Apocrine differentiation in breast cancer appears to be an independent predictor of poor prognosis tumours.

show abstract

Section: Prognostic Factorssupporting

confidence: 88%

Section: Prognostic Factorsmentioning

confidence: 95%

Is apocrine differentiation in breast carcinoma of prognostic significance?

Bundred

Walker²,

Everington³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…For all these reasons, the incidence of reported immunocytochemically positive tumours varies between 12 and over 50% (8,18,19,20). Sixty-three per cent of the present cases were GCDFP-15 positive.…”

Section: Discussionmentioning

confidence: 62%

“…The observation by Haagensen and co-workers (13) that the glycoprotein of 15 kDa present in the breast cyst fluid was selectively produced in the apocrine epithelium provided a sensitive and specific functional marker for monitoring and defining apocrine differentiation in breast carcinomas especially in neoplastic conditions. Numerous authors have established the incidence and significance of apocrine differentiation in breast carcinomas, employing immunocytochemical procedures for localizing the GCDFP-15 marker (8,12,13,18,19,20,34). It was soon realized that this type of differentiation is detectable both in in situ and in invasive carcinomas (7).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast

Pagani

Sapino

Bergnolo

et al. 1994

Vichows Archiv A Pathol Anat

View full text Add to dashboard Cite

The frequency and the significance of apocrine differentiation in carcinomas of the breast are uncertain, because of the lack of reliable and reproducible criteria for morphological diagnosis. The 15 kDa glycoprotein of cystic breast disease (GCDFP-15) is regarded as a specific functional marker of apocrine cells. Expression of the prolactin-inducible protein (PIP)/GCDFP-15 gene was investigated by Northern blot analysis and in situ hybridization in breast cancer cell lines and in an unselected series (33 cases) of primary carcinomas of the breast. On the same cases, histological assessment of apocrine differentiation and immunocytochemical detection of GCDFP-15 were also performed and correlated with follow-up data. The presence of PIP/GCDFP-15 mRNA was a feature of a relatively high number of cases, but was incompletely correlated with histological and immunocytochemical evidences of apocrine differentiation. Expression of the PIP/GCDFP-15 gene was significantly associated with relapse-free survival, and may represent a novel variable of functional and prognostic relevance.

show abstract

Expression of GCDFP-15 in breast carcinomas. Relationship to pathologic and clinical factors

Mazoujian

Bodian

Haagensen

et al. 1989

Cancer

View full text Add to dashboard Cite

A retrospective immunoperoxidase staining study for a glycoprotein isolated from human breast gross cystic disease fluid (GCDFP-15) in 562 primary breast carcinomas in 539 patients was conducted to correlate its immunohistochemistry with pathologic and clinical factors. Overall, 55% of the carcinomas studied stained positively for GCDFP-15. In certain histologic subtypes, the percentage of carcinomas that stained positively was greater: those subtypes with apocrine histologic features (75%), intraductal carcinoma (70%), and infiltrating lobular carcinoma with signet-ring cell differentiation (90%). In contrast, only 5% of medullary carcinomas exhibited positive staining. Only 23% of breast carcinomas without apocrine features stained positively for GCDFP-15. Carcinomas that stained positively were more likely to have involved axillary lymph nodes (P less than 0.054). The staining was independent of nuclear grade, mitotic index, tumor size, and estrogen receptor status. Positive staining was related to a history of gross cystic disease but not to age, parity, menopausal status, or age at first birth. A positive stain was not related to risk of recurrence or survival.

show abstract

Immunohistochemistry of a component protein of the breast cystic disease fluid with mol. wt 15,000

Cited by 24 publications

References 17 publications

Is apocrine differentiation in breast carcinoma of prognostic significance?

Is apocrine differentiation in breast carcinoma of prognostic significance?

PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast

Expression of GCDFP-15 in breast carcinomas. Relationship to pathologic and clinical factors

Contact Info

Product

Resources

About